KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
119 hedge funds and large institutions have $568M invested in KalVista Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 28 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 33
2% more capital invested
Capital invested by funds: $557M → $568M (+$11M)
7% less funds holding
Funds holding: 128 → 119 (-9)
15% less call options, than puts
Call options by funds: $373K | Put options by funds: $441K
21.63% less ownership
Funds ownership: 135.96% → 114.33% (-22%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$20.6M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$19.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.6M |
| 4 |
BlackRock
New York
|
+$5.99M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$13.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.77M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.13M |
| 4 |
SC
Stempoint Capital
New York
|
-$4.95M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.58M |
KALV Hedge Fund Activity: Q2 2024 in Review
119 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2024, worth a combined $568M — up 2% from $557M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KALV and 19 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 45 added.
The largest buyer was Capital World Investors, adding an estimated $20.6M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $13.8M sold.
- 119 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2024, down from 128 in Q1 2024.
- Funds reported $568M of KalVista Pharmaceuticals stock for Q2 2024, up 2% quarter-over-quarter.
- 19 funds opened new KalVista Pharmaceuticals positions in Q2 2024 and 28 closed out, a net change of -9 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2024 was Capital World Investors, an estimated $20.6M added.
- The largest KalVista Pharmaceuticals seller in Q2 2024 was TCG Crossover Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2024.